The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Gene Review

H22  -  histocompatibility 22

Mus musculus

Synonyms: H-22
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of H22

  • EXPERIMENTAL DESIGN AND RESULTS: In this study, a chicken homologous Tie-2 protein vaccine (chTie-2) and a corresponding mouse Tie-2 vaccine as a control were prepared and the antitumor effect of these vaccines was tested in two tumor models (murine B16F10 melanoma and murine H22 hepatoma) [1].
  • The antitumor activity of liposomal quercetin was evaluated in the immunocompetent C57BL/6N mice bearing LL/2 Lewis lung cancer and in BALB/c mice bearing CT26 colon adenocarcinoma and H22 hepatoma [2].
  • The unmodified and PEGylated rhES were tested for their ability to inhibit the tumor growth of mouse H22 liver cancer in male mice [3].
  • In Sarcoma-180 (S180) and Hepatoma-22 (H22) tumor bearing mice models, the inhibition rates were 55.9 and 55.6%, respectively, at the doses of DL111-IT 12.5-50.0 mg/kg for 9 days consecutive administration [4].
  • In this study, we evaluated the antitumor activity of the combination therapy in the immunocompetent BALB/c mice bearing H22 hepatoma and Meth A fibrosarcoma, respectively [5].

High impact information on H22

  • This molecule, wH22xeGFP, consists of the entire humanized anti-FcgammaRI mAb H22 with eGFP genetically fused to the C-terminal end of each CH3 domain. wH22xeGFP binds within the ligand-binding region by its Fc end, as well as outside the ligand-binding region by its Fab ends, thereby cross-linking FcgammaRI [6].
  • Furthermore, HCC49x H22 was shown to simultaneously bind to KLEB cells and a soluble FcgammaRI fusion protein, demonstrating the bifunctional nature of the molecule [7].
  • Subcutaneous H22 tumors established in BALB/c mice were completely eradicated in response to intratumoral injection of B7H3-expressing plasmids followed 24h later by vasostatin-expressing plasmids [8].
  • Combination therapy generated potent systemic antitumor immunity mediated by CD8(+) and NK cells that was effective in combating a systemic challenge of 1 x 10(7) parental H22 cells [9].
  • These studies demonstrate that mAb H22 blocked phagocytosis of opsonized red blood cells 1000 times more effectively than an irrelevant IgG [10].

Chemical compound and disease context of H22


Biological context of H22

  • The utility and sensitivity of this procedure were verified with a Chromosome (Chr) 16-specific cosmid probe, H22, as well as with the mapping of a high-copy-number human beta-amyloid/A4 transgene [16].
  • RES could induce the S phase arrest of H22 cells, and increase the percentage of cells in S phase from 59.1% (n = 9) to 73.5% (n = 9) in a dose-dependent manner (P<0.05) [13].
  • H22 cell cycles were analyzed with flow cytometry [13].
  • In vitro studies demonstrated that As2O3 inhibited the proliferation of H22 tumor cells and bovine aortic endothelial cells, and induced their apoptosis in a dose- and time-dependent fashion, suggesting that the mechanism of As2O3-mediated inhibition of tumor growth is due to direct effects of the drug on both tumor cells and endothelia [17].
  • RESULTS: The hybridomas of DCs and H22 cells acquired both DCs and H22 cells phenotypes [18].

Anatomical context of H22


Associations of H22 with chemical compounds

  • The antitumor effect of resveratrol might be related to directly inhibiting the growth of H22 cells and indirectly inhibiting its potential effect on nonspecific host immunomodulatory activity [23].
  • Furthermore, the polysaccharide (PS) extracted from fungus G1 and its antioxidant activity on H22-bearing mice was investigated [24].
  • BALB/c mice bearing hepatocarcinoma cell line H22 were treated with naked pVAX-sEN or liposome-DNA complex in which the dose of DNA and the ratio of DNA and liposome were different from each other [25].
  • METHODS: Fusion cells of dendritic cells (DCs) and H22 cells were prepared with polyethylene glycol [18].
  • FLCJ, pectolinarin and 5, 7-dihydroxy-6, 4'-dimethoxyflavone can inhibit the growth of the implanted tumors S180 and H22 and promote cellular and humoral immune responses [26].

Regulatory relationships of H22


Other interactions of H22

  • Lewis lung carcinoma and solid H22 hepatoma treated with 50-250 mg/kg CTX for 3 h lost TrxR activity in a dose-dependent fashion [29].
  • The peak serum TNF alpha levels were 95.7 +/- 16.4 ng/mL and 80.7 +/- 14.9 ng/mL in the H22 and control groups, respectively [30].
  • Treatment with H22, a monoclonal antibody to gamma interferon (IFN-gamma), also gave significant protection against death and, in addition, did lead to a decrease in the level of induction of the hepatic NOS [31].
  • MDX-H210, constructed by crosslinking antigen binding fragments (F(ab') fragments) of monoclonal antibody (mAb) H22 to Fc gamma receptor I (FcgammaRI), and mAb 520C9 to HER-2/neu, respectively, mediates the lysis of tumour cells in vitro, and in human FcgammaRI transgenic mouse models [32].
  • The effect of alkaloid from Oxytropis ochrocephala on growth inhibition and expression of PCNA and p53 in mice bearing H22 Hepatocellular Carcinoma [33].

Analytical, diagnostic and therapeutic context of H22


  1. Immunotherapy of tumors with protein vaccine based on chicken homologous Tie-2. Luo, Y., Wen, Y.J., Ding, Z.Y., Fu, C.H., Wu, Y., Liu, J.Y., Li, Q., He, Q.M., Zhao, X., Jiang, Y., Li, J., Deng, H.X., Kang, B., Mao, Y.Q., Wei, Y.Q. Clin. Cancer Res. (2006) [Pubmed]
  2. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Yuan, Z.P., Chen, L.J., Fan, L.Y., Tang, M.H., Yang, G.L., Yang, H.S., Du, X.B., Wang, G.Q., Yao, W.X., Zhao, Q.M., Ye, B., Wang, R., Diao, P., Zhang, W., Wu, H.B., Zhao, X., Wei, Y.Q. Clin. Cancer Res. (2006) [Pubmed]
  3. Preparation and stability of N-terminal mono-PEGylated recombinant human endostatin. Nie, Y., Zhang, X., Wang, X., Chen, J. Bioconjug. Chem. (2006) [Pubmed]
  4. Antiproliferative activity of contragestazol (DL111-IT) in murine and human tumor models in vitro and in vivo. Yang, B., He, Q.J., Zhu, D.Y., Lou, Y.J., Fang, R.Y. Cancer Chemother. Pharmacol. (2006) [Pubmed]
  5. Systemic inhibition of tumor growth by soluble Flk-1 gene therapy combined with cisplatin. Wang, R., Zhang, X.W., Wang, G.Q., Chen, X.C., Tian, L., Yang, H.S., Hu, M., Peng, F., Yang, J.L., He, Q.M., Zhang, W., Jiang, Y., Deng, H.X., Wen, Y.J., Li, J., Zhao, X., Wei, Y.Q. Cancer Gene Ther. (2006) [Pubmed]
  6. Colocalization of Fc gamma RI-targeted antigen with class I MHC: implications for antigen processing. Guyre, C.A., Barreda, M.E., Swink, S.L., Fanger, M.W. J. Immunol. (2001) [Pubmed]
  7. Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells. Russoniello, C., Somasundaram, C., Schlom, J., Deo, Y.M., Keler, T. Clin. Cancer Res. (1998) [Pubmed]
  8. Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. Ma, L., Luo, L., Qiao, H., Dong, X., Pan, S., Jiang, H., Krissansen, G.W., Sun, X. J. Hepatol. (2007) [Pubmed]
  9. Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas. Luo, L., Qiao, H., Meng, F., Dong, X., Zhou, B., Jiang, H., Kanwar, J.R., Krissansen, G.W., Sun, X. Int. J. Cancer (2006) [Pubmed]
  10. Humanized mAb H22 binds the human high affinity Fc receptor for IgG (FcgammaRI), blocks phagocytosis, and modulates receptor expression. Wallace, P.K., Keler, T., Coleman, K., Fisher, J., Vitale, L., Graziano, R.F., Guyre, P.M., Fanger, M.W. J. Leukoc. Biol. (1997) [Pubmed]
  11. Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer. Yu, L., Sun, Z.J., Wu, S.L., Pan, C.E. World J. Gastroenterol. (2003) [Pubmed]
  12. Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma. Zhu, B.D., Yuan, S.J., Zhao, Q.C., Li, X., Li, Y., Lu, Q.Y. World J. Gastroenterol. (2005) [Pubmed]
  13. Effect of resveratrol and in combination with 5-FU on murine liver cancer. Wu, S.L., Sun, Z.J., Yu, L., Meng, K.W., Qin, X.L., Pan, C.E. World J. Gastroenterol. (2004) [Pubmed]
  14. Exoproducts of the Escherichia coli strain H22 inhibiting some enteric pathogens both in vitro and in vivo. Cursino, L., Smajs, D., Smarda, J., Nardi, R.M., Nicoli, J.R., Chartone-Souza, E., Nascimento, A.M. J. Appl. Microbiol. (2006) [Pubmed]
  15. In vivo antitumor activity of chitosan nanoparticles. Qi, L., Xu, Z. Bioorg. Med. Chem. Lett. (2006) [Pubmed]
  16. The mapping of transgenes by fluorescence in situ hybridization on G-banded mouse chromosomes. Shi, Y.P., Huang, T.T., Carlson, E.J., Epstein, C.J. Mamm. Genome (1994) [Pubmed]
  17. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Liu, B., Pan, S., Dong, X., Qiao, H., Jiang, H., Krissansen, G.W., Sun, X. Cancer Sci. (2006) [Pubmed]
  18. Antitumor effect of immunization with fusion of dendritic cells and hepatocellular carcinoma cells in mice. Zhang, H., Zheng, S.S., Jiang, G.P., Wu, L.H., Zhu, F., Yang, Z.L. HBPD INT (2004) [Pubmed]
  19. Cytotoxicity of anti-CD64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice. Zhong, R.K., van de Winkel, J.G., Thepen, T., Schultz, L.D., Ball, E.D. J. Hematother. Stem Cell Res. (2001) [Pubmed]
  20. Effect of Haimiding on the functioning of red cell membrane of FC and H22 tumor-bearing mice. Ji, Y.B., Gao, S.Y., Cheng, W.P. World J. Gastroenterol. (2005) [Pubmed]
  21. Antitumor and synergistic effect of Chinese medicine "bushen huayu jiedu recipe" and chemotherapy on transplanted animal hepatocarcinoma. Cao, Y., Xia, Q.H., Meng, H., Zhong, A.P. World J. Gastroenterol. (2005) [Pubmed]
  22. Effect of hepatoma H22 on lymphatic endothelium in vitro. Yu, H., Zhou, H.Z., Wang, C.M., Gu, X.M., Pan, B.R. World J. Gastroenterol. (2004) [Pubmed]
  23. Antitumor and immunomodulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice. Liu, H.S., Pan, C.E., Yang, W., Liu, X.M. World J. Gastroenterol. (2003) [Pubmed]
  24. Morphological and genetic characterization of a cultivated Cordyceps sinensis fungus and its polysaccharide component possessing antioxidant property in H22 tumor-bearing mice. Chen, J., Zhang, W., Lu, T., Li, J., Zheng, Y., Kong, L. Life Sci. (2006) [Pubmed]
  25. Human endostatin gene transfer, either naked or with liposome, has the same inhibitory effect on growth of mouse liver tumor cells in vivo. Ma, C.H., Zhang, Y., Wang, X.Y., Gao, L.F., Liu, H., Guo, C., Liu, S.X., Cao, Y.L., Zhang, L.N., Sun, W.S. World J. Gastroenterol. (2004) [Pubmed]
  26. Tumor inhibition and improved immunity in mice treated with flavone from Cirsium japonicum DC. Liu, S., Luo, X., Li, D., Zhang, J., Qiu, D., Liu, W., She, L., Yang, Z. Int. Immunopharmacol. (2006) [Pubmed]
  27. Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy. He, Y.F., Wang, X.H., Zhang, G.M., Chen, H.T., Zhang, H., Feng, Z.H. Cancer Immunol. Immunother. (2005) [Pubmed]
  28. Lymphotactin enhances the in-vitro immune efficacy of dendritoma formed by dendritic cells and mouse hepatocellular carcinoma cells. Zhang, H., Jiang, G.P., Zheng, S.S., Wu, L.H., Zhu, F., Yang, Z.L. J. Zhejiang Univ. Sci. (2004) [Pubmed]
  29. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo. Wang, X., Zhang, J., Xu, T. Toxicol. Appl. Pharmacol. (2007) [Pubmed]
  30. Role of interferon-gamma in experimental gram-negative sepsis. Silva, A.T., Cohen, J. J. Infect. Dis. (1992) [Pubmed]
  31. Differential effects of monoclonal antibodies to tumor necrosis factor alpha and gamma interferon on induction of hepatic nitric oxide synthase in experimental gram-negative sepsis. Evans, T., Carpenter, A., Silva, A., Cohen, J. Infect. Immun. (1992) [Pubmed]
  32. Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. Repp, R., van Ojik, H.H., Valerius, T., Groenewegen, G., Wieland, G., Oetzel, C., Stockmeyer, B., Becker, W., Eisenhut, M., Steininger, H., Deo, Y.M., Blijham, G.H., Kalden, J.R., van de Winkel, J.G., Gramatzki, M. Br. J. Cancer (2003) [Pubmed]
  33. The effect of alkaloid from Oxytropis ochrocephala on growth inhibition and expression of PCNA and p53 in mice bearing H22 Hepatocellular Carcinoma. Long, L., Li, Q. Yakugaku Zasshi (2005) [Pubmed]
  34. Antitumor immunopreventive and immunotherapeutic effect in mice induced by hybrid vaccine of dendritic cells and hepatocarcinoma in vivo. Zhang, J.K., Li, J., Zhang, J., Chen, H.B., Chen, S.B. World J. Gastroenterol. (2003) [Pubmed]
WikiGenes - Universities